Expertise in
16
conditions
Expertise in
16
conditions
1201 West La Veta Avenue, 
Orange, CA 

Overview

Elyssa Rubin is a Pediatric Hematologist Oncology provider in Orange, California. Dr. Rubin is highly rated in 16 conditions, according to our data. Her top areas of expertise are Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration. Dr. Rubin is currently accepting new patients.

Her clinical research consists of co-authoring 10 peer reviewed articles and participating in 49 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatric Hematology-Oncology in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

1201 West La Veta Avenue, Orange, CA 92868

Additional Areas of Focus

Dr. Rubin has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


49 Clinical Trials

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Neuroblastoma Biology Studies
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)
View 48 Less Clinical Trials
Similar Doctors
Expertise in
27
conditions
Pediatric Hematology Oncology
Expertise in
27
conditions
Pediatric Hematology Oncology
1201 West La Veta Avenue, 
Orange, CA 
 (0.1 miles away)
Languages Spoken:
English
Accepting New Patients

Mariko Sato is a Pediatric Hematologist Oncology provider in Orange, California. Dr. Sato is highly rated in 27 conditions, according to our data. Her top areas of expertise are Glioma, Medulloblastoma, Hepatoblastoma, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Aspiration. Dr. Sato is currently accepting new patients.

Expertise in
18
conditions
Pediatric Hematology Oncology
Expertise in
18
conditions
Pediatric Hematology Oncology
1201 West La Veta Avenue, 
Orange, CA 
 (0.1 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Diane Nugent is a Pediatric Hematologist Oncology provider in Orange, California. Dr. Nugent is highly rated in 18 conditions, according to our data. Her top areas of expertise are Blood Clots, Hemophilia A, Immune Thrombocytopenic Purpura (ITP), and Sickle Cell Disease. Dr. Nugent is currently accepting new patients.

Expertise in
17
conditions
Pediatric Hematology Oncology
Expertise in
17
conditions
Pediatric Hematology Oncology
1201 West La Veta Avenue, 
Orange, CA 
 (0.1 miles away)
Languages Spoken:
English
Accepting New Patients

Pournima Navalkele is a Pediatric Hematologist Oncology provider in Orange, California. Dr. Navalkele is highly rated in 17 conditions, according to our data. Her top areas of expertise are Medulloblastoma, Glioma, Acute Lymphoblastic Leukemia (ALL), and Ganglioglioma. Dr. Navalkele is currently accepting new patients.

Frequently Asked Questions about Dr. Elyssa M. Rubin

How do I make an appointment with Dr. Elyssa M. Rubin?

You can book an appointment with Dr. Elyssa M. Rubin by calling their office at 714-509-8636. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Elyssa M. Rubin a top-rated expert for Ewing Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Elyssa M. Rubin is classified as an Distinguished expert for Ewing Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Elyssa M. Rubin specialize in?

While Dr. Elyssa M. Rubin is a Pediatric Hematology Oncology, they have specific expertise in Ewing Sarcoma, Osteosarcoma, and Neuroblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Hematology Oncology.

Does Dr. Elyssa M. Rubin participate in research or clinical trials?

Yes. Dr. Elyssa M. Rubin has published 10 articles and abstracts on conditions like Ewing Sarcoma. You can view a list of Dr. Elyssa M. Rubin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Elyssa M. Rubin accept my insurance?

Dr. Elyssa M. Rubin accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 714-509-8636 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rubin's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile